Amgen (AMGN) Tops Q4 EPS by 42c

Amgen (NASDAQ: AMGN) reported Q4 EPS of $3.81, $0.42 better than the analyst estimate of $3.39. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.58 billion.

GUIDANCE:

Amgen sees FY2021 EPS of $16.00-$17.00, versus the consensus of $17.02. Amgen sees FY2021 revenue of $25.8-26.6 billion, versus the consensus of $26.43 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Pacific Bio (PACB) says prelim. revenue for Q1 was below expectations due to customers delaying instrument purchases
• Bank of America (BAC) Tops Q1 EPS by $0.07, Beats on Revenue
• Morgan Stanley CEO: investment banking momentum is building - Conference Call